Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.
Epistemonikos ID: 7f3482f535e94a31c2feb7a2f98224a81b664976
First added on: May 13, 2024